Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?

Kidney International

Volumn 69, Issue 8, 2006, Pages 1293-1295

  Jacobsen, P K ^a   Tarnow, L ^a   Parving, H H ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN;

ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG RESPONSE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; META ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 33646132994     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000283     Document Type: Note

References (11)

1. Jacobsen PK. Preventing end stage renal disease in diabetic patients: genetic aspect (part I). J Renin Angiotensin Aldosterone Syst 2005;6:1-14.
2. Rossing K, Christensen PK, Hovind P et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004;66:1596-1605.
3. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-549.
4. So WY, Ma RCW, Ozaki R et al. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients: interaction with ACE insertion/deletion polymorphism. Kidney Int 2006;69: 1438-1443.
5. Ng DP, Tai BC, Koh D et al. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 2005;48:1008-1016.
6. Parving H-H, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996;313:591-594.
7. Jacobsen P, Tarnow L, Carstensen B et al. Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 2003;14:2843-2850.
8. Penno G, Chaturvedi N, Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998;47:1507-1511.
9. Ruggenenti P, Perna A, Zoccali C et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen) J Am Soc Nephrol 2000;11: 88-96.
10. Andersen S, Tarnow L, Cambien F et al. Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 2003;26:1501-1506.
11. van der Kleij FG, de Jong PE, Henning RH et al. Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 2002;13:1025-1033.